Entrada Therapeutics (TRDA) Total Current Liabilities (2022 - 2025)
Historic Total Current Liabilities for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $24.0 million.
- Entrada Therapeutics' Total Current Liabilities fell 6598.02% to $24.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.0 million, marking a year-over-year decrease of 6598.02%. This contributed to the annual value of $39.5 million for FY2024, which is 7513.67% down from last year.
- Latest data reveals that Entrada Therapeutics reported Total Current Liabilities of $24.0 million as of Q3 2025, which was down 6598.02% from $19.8 million recorded in Q2 2025.
- In the past 5 years, Entrada Therapeutics' Total Current Liabilities registered a high of $173.9 million during Q1 2024, and its lowest value of $15.4 million during Q1 2022.
- Over the past 4 years, Entrada Therapeutics' median Total Current Liabilities value was $39.5 million (recorded in 2024), while the average stood at $73.8 million.
- As far as peak fluctuations go, Entrada Therapeutics' Total Current Liabilities soared by 85678.72% in 2023, and later crashed by 8940.37% in 2025.
- Entrada Therapeutics' Total Current Liabilities (Quarter) stood at $22.0 million in 2022, then skyrocketed by 622.72% to $158.8 million in 2023, then tumbled by 75.14% to $39.5 million in 2024, then plummeted by 39.16% to $24.0 million in 2025.
- Its last three reported values are $24.0 million in Q3 2025, $19.8 million for Q2 2025, and $18.4 million during Q1 2025.